Clinical applications of molecular haematology: JAK2 in myeloproliferative disorders.
Article
Dans Anglais
| IMSEAR
| ID: sea-85642
ABSTRACT
Molecular markers are helpful in diagnosis, prognosis and management of haematological malignancies. Recently, a single point mutation in the Janus Kinase 2 (JAK2) gene in the Philadelphia-negative myeloproliferative disorders, including polycythemia vera (over 95%), essential thrombocythemia (50%) and primary myelofibrosis (50%) was identified by several groups. This mutation is now considered to have a fundamental role in the pathogenesis of these disorders. A PCR-based test from peripheral blood has become available in India to detect this mutation. Present article discusses the basic aspects of this mutation and its value in diagnosing, prognosticating and treating patients of suspected chronic myeloproliferative disorders.
Texte intégral:
Disponible
Indice:
IMSEAR (Asie du Sud-Est)
Sujet Principal:
Polyglobulie primitive essentielle
/
Pronostic
/
Humains
/
Marqueurs génétiques
/
Kinase Janus-2
/
Myélofibrose primitive
/
Thrombocytémie essentielle
/
Biologie moléculaire
/
Mutation
/
Syndromes myéloprolifératifs
Type d'étude:
Étude pronostique
langue:
Anglais
Année:
2007
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS